KUALA LUMPUR, Dec 6 -- LintonPharm Co Ltd, a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announced the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab, a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers,” said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm.
“Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention.
“Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
According to a statement, a recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC.
It is noted that catumaxomab was well tolerated and presented promising performance in tumour control. Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 per cent are diagnosed as NMIBC. Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG.
For more information, visit www.lintonpharm.com.
-- BERNAMA
No comments:
Post a Comment